ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology firm focused on developing innovative therapies for cancer patients. At the forefront of its pipeline is ALX148, a CD47 blocking therapeutic, which is progressing through Phase 1b/2 clinical trials. This candidate is being evaluated for a variety of hematologic malignancies, including myelodysplastic syndromes, acute myeloid leukemia, and non-Hodgkin's lymphoma. Additionally, it targets a range of solid tumors, such as head and neck squamous cell carcinoma, HER2-positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumor indications. Beyond its lead candidate, ALX Oncology's pre-clinical portfolio includes ALTA-002, a SIRPa TRAAC designed to engage both the innate and adaptive immune systems in the fight against cancer. The company maintains a robust network of strategic collaborations, including a Phase 2 trial with Merck evaluating ALX148 in combination with pembrolizumab (with or without chemotherapy) for head and neck cancer. Another partnership involves Zymeworks for a Phase 1 trial assessing ALX148 alongside the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors. Furthermore, ALX Oncology collaborates with Tallac Therapeutics for the development, manufacturing, and commercialization of a novel class of cancer immunotherapeutics. Further bolstering its capabilities are licensing agreements with Selexis SA and Crystal Bioscience, Inc. Founded in 2015, the company operates from its headquarters in South San Francisco, California.

CEO: Jason W. Lettmann - https://www.alxoncology.com